• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection

tetano

Editor, Senior Moderator
Front Immunol


. 2023 Oct 18:14:1270081.
doi: 10.3389/fimmu.2023.1270081. eCollection 2023. The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection

Déborah Lécuyer[SUP] 1 2 [/SUP], Roberta Nardacci[SUP] 3 4 [/SUP], Désirée Tannous[SUP] 1 2 5 [/SUP], Emie Gutierrez-Mateyron[SUP] 1 2 [/SUP], Aurélia Deva Nathan[SUP] 1 2 [/SUP], Frédéric Subra[SUP] 6 [/SUP], Cristina Di Primio[SUP] 7 8 [/SUP], Paola Quaranta[SUP] 7 9 [/SUP], Vanessa Petit[SUP] 10 [/SUP], Clémence Richetta[SUP] 6 [/SUP], Ali Mostefa-Kara[SUP] 1 2 [/SUP], Franca Del Nonno[SUP] 3 [/SUP], Laura Falasca[SUP] 3 [/SUP], Romain Marlin[SUP] 11 [/SUP], Pauline Maisonnasse[SUP] 11 [/SUP], Julia Delahousse[SUP] 1 2 [/SUP], Juliette Pascaud[SUP] 11 12 [/SUP], Eric Deprez[SUP] 6 [/SUP], Marie Naigeon[SUP] 2 13 14 [/SUP], Nathalie Chaput[SUP] 13 14 15 [/SUP], Angelo Paci[SUP] 1 2 14 16 [/SUP], Véronique Saada[SUP] 16 [/SUP], David Ghez[SUP] 1 17 [/SUP], Xavier Mariette[SUP] 11 12 18 [/SUP], Mario Costa[SUP] 7 8 19 [/SUP], Mauro Pistello[SUP] 9 20 [/SUP], Awatef Allouch[SUP] 1 2 5 [/SUP], Olivier Delelis[SUP] 6 [/SUP], Mauro Piacentini[SUP] 3 21 [/SUP], Roger Le Grand[SUP] 11 [/SUP], Jean-Luc Perfettini[SUP] 1 2 [/SUP]



Affiliations
Abstract

Purinergic receptors and NOD-like receptor protein 3 (NLRP3) inflammasome regulate inflammation and viral infection, but their effects on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain poorly understood. Here, we report that the purinergic receptor P2X7 and NLRP3 inflammasome are cellular host factors required for SARS-CoV-2 infection. Lung autopsies from patients with severe coronavirus disease 2019 (COVID-19) reveal that NLRP3 expression is increased in host cellular targets of SARS-CoV-2 including alveolar macrophages, type II pneumocytes and syncytia arising from the fusion of infected macrophages, thus suggesting a potential role of NLRP3 and associated signaling pathways to both inflammation and viral replication. In vitro studies demonstrate that NLRP3-dependent inflammasome activation is detected upon macrophage abortive infection. More importantly, a weak activation of NLRP3 inflammasome is also detected during the early steps of SARS-CoV-2 infection of epithelial cells and promotes the viral replication in these cells. Interestingly, the purinergic receptor P2X7, which is known to control NLRP3 inflammasome activation, also favors the replication of D614G and alpha SARS-CoV-2 variants. Altogether, our results reveal an unexpected relationship between the purinergic receptor P2X7, the NLRP3 inflammasome and the permissiveness to SARS-CoV-2 infection that offers novel opportunities for COVID-19 treatment.

Keywords: COVID-19; NLRP3; P2X7; SARS-CoV-2; inflammasome.

 
Back
Top Bottom